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ABSTRACT: Therapeutic monoclonal antibodies (mAbs) market is strongly contributing to 
the rising growth of the biotechnology industry. Despite the increasing number of inventions 
over time, a few therapeutic mAbs are currently marketed. This paper focuses on developing 
an emerging score to select/rank promising therapeutic mAbs patents, based on a hierarchical 
decision model using expert's opinion. Six attributes related to each factor concerning patent 
status, patent owner's profile and mAbs medical relevance were analyzed. The desirability 
levels of each attribute were also assessed. Our data shows the medical relevance factor as the 
most important, contributing 50% of the emerging score. Among the attributes, the most 
important under patent status was proper geographic coverage and wider patent scope; for 
organization’s profile was the preexistence of approved drugs; and for medical relevance, the 
clinical phase performance. A group of 1053 patents related to therapeutic mAb were scored, 
and the most promising were concerning combination therapy using immune checkpoint 
inhibitors. The study has managerial implications related to patent portfolio management and 
patent valuation, and provides instructions to rank mAbs patents according to the emerging 
score defined by attribute’s importance in order to improve the identification of future 
innovations pathways. 
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1. INTRODUCTION 
 
The biotechnology industry is technology emergence sector which facing a remarkable 
growth recently. The worldwide market was estimated at USD 369.62 billion in 2016 and is 
projected to reach $727.1 billion by 2025 (Grand View Research, 2017). It is remarkably 
transforming the United States (US) economy, the country with the largest biotech sector. The 
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contribution of the industry to the US economy was estimated to represent more than 2% of 
the gross domestic product (GDP) and, from 2007 to 2012, the biotech aggregates revenue 
have grown more than 10% on annual average rate, much faster than the US general economy 
(Carlson, 2016).  The progress of the industry is mainly motivated by factors such as massive 
R&D investments, intense use of intellectual property rights and also the establishment of 
partnership and strategic alliances (Evens and Kaitin, 2014). High investments in such factors 
contribute directly to an increased number of biopharmaceuticals in clinical development. 
There was a rise of 245% on the number of drug candidates from 2001 to 2012 (PhRMA, 
2013). The biggest was seen by the monoclonal antibody (mAb) class which rose 351% over 
the 11 years of analysis, starting from 338 molecules under development to 901 in 2012. 
Monoclonal antibodies are not only the highest biopharmaceuticals class in development, they 
are also the most approved in the US and Europe (Walsh, 2014). Nevertheless, behind the 
regulatory steps, resides the strength of intellectual property rights. The commercialization 
process evaluates a patent value. Gans, and Stern, (2003.p. 348) pointed out that 
commercialization strategy environment embraces its own vulnerabilities and possible 
opportunities.  Technological spillover enables rivals to follow up original endeavors, and 
even took advantage of quickly catch up or “invent around” already claimed the original of 
invention (Chadha & Oriani, 2010; Liu et al., 2018). Although, real view of the possibility of 
a patent being affected in litigation prevails unclear without fully examining managerial 
awareness, which is directed and classified heterogeneously within a company. Ardito et al., 
2015 investigated how the costs and benefits of a comprehensive search in green energy - 
general purpose technologies progress depends on structure within two teams, size dimension 
and geographic distribution across countries. Eusebi and Silberglitt (2014, p. 1) defined a 
possible value metric for technology transfer staff with the emergence s-curve, by classifying 
patents in positions of their distance from the year of appearance whether they are “leading” 
or “following” the profitmaking attentiveness in the field and features of patent networks.  
Due technological uncertainty companies are searching the best model to acquire the 
relevance and consequence from patent status and in this case the medical significance of the 
mAbs patent. 
The patent universe, especially for mAbs, is extremely vast and diverse which, 
consequently, result in a discrepancy between the number of drugs that actually reach clinical 
development and the patented discoveries. Considering the high cost and risk of failure during 
the clinical development (Morgan et al., 2011), companies need to manage their intellectual 
property to assess technology value and set strategies to invest on emerging technologies. In 
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this regard, decision-making is a fundamental process for drug development companies to 
select the best alternatives for investment (Jekunen, 2014). Since patents guarantee the 
exclusivity on the commercial exploration of their technologies, forecasting the most 
promising mAbs therapies based on their many intrinsic criteria seems a consistent strategy 
for a biotech company to identify emerging technologies.    
Although the subject is relevant, there are few studies that show the association of 
multicriteria decision-making methods aiming to rank/score technologies on patent-level in 
biotechnology. And the availability of studies is even more limited when the approach is used 
to assess the technology potential on a large pool of alternatives of a specific sector such as 
therapeutic mAbs. The present study comes to add to the current literature by presenting the 
novelty of associating a hierarchical decision model (HDM) and patent analysis, in order to 
predict the technology emergence according to an emerging score (ES). Indicators for 
technology emergence can contribute to R&D policy and portfolio management, as well as 
analysis of technology opportunities to indicate priorities and manage innovation (Porter and 
Detampel, 1995). In the context of this research, the technology emergence that we aim to 
identify concerns the prediction of new molecules of monoclonal antibodies for therapeutic 
use, taking into account the quality of the intellectual property involved in the technology, the 
company's strength to drive any therapy to the late-stage of clinical phase, and the intrinsic 
molecular and functional characteristics of the mAbs. 
In face of that, our research aimed to develop an ES for therapeutic mAbs based on 
HDM. The score was calculated after expert’s quantitation of several factors and its attributes 
that influence the success of the therapeutic mAbs, and it was used to further assess, rank, and 
predict promising patents. Firstly, we have identified and described the factors and its related 
attributes that influence the mAbs success based on literature and expert’s opinion. Factors 
were relative to the attributes of the patent, the company which holds the technology, and 
clinical relevance of a mAbs. Secondly, their relative importance was quantified based on 
expert’s pair-wise comparison. Finally, we ended up with a list of the overall significance of 
factors and attributes for a certain patent to be considered emerging.  In this case, the 
alternatives were patents related to therapeutic mAbs, which were scored and ranked to 
forecast emerging mAbs. The following section brings a literature review discussing and 
connecting the main topics of our research with the present literature, including also a brief 
patent landscape of the sector as described by Pereira and Porto (2018). A detailed research 
framework follows, describing the steps for building, validation, quantification, and 
application of the model. Next is a section with the results, stating the attribute’s relative 
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importance, their least and most desirable levels, and the patent scoring highlighting the top 
10 most promising technologies according to the model. Finally, we discuss the results 
pointing its implications, limitations, and scope of applications.  
 
2. BACKGROUND 
  2.1. Biotechnology industry and the therapeutic monoclonal antibody market 
The biotechnology is one of the fast-growing industries in the world. The growth of the 
sector is mainly driven by their applications in healthcare, which differs from the traditional 
pharmaceuticals by the nature of their drugs. While biotechnology companies develop their 
drugs on a biological basis using living organisms, the pharmaceutical uses traditional 
chemical-base drugs. Although biotechnology has a wider scope of its applications and higher 
operating cost (Edelman, 2004), both sectors intersect and complement each other (Rader, 
2008). 
The major product categories are biopharmaceuticals, which include large-molecule 
proteins; peptides; monoclonal antibodies; cell, tissue, and genetic therapies; and many others. 
Most profits from biopharmaceuticals comes from monoclonal antibodies (mAb), which sales 
in 2016 represented 66% of the total market (excluding vaccines) - a total of 106.9 billion 
dollars (La Merie Publishing, 2017). Five of the top 10 drugs sold in 2016 were mAbs 
(Kennedy et al., 2017). 
Monoclonal antibodies are produced by a single clone of lymphocyte B and are 
designed to target a particular antigen. Therapeutically, mAbs were introduced in the 90’s and 
are currently being used in therapies for cancer, inflammatory, cardiovascular and infectious 
diseases, organ transplantations, and many other applications. The growth of therapeutic 
mAbs market was significantly leveraged by the improvement of our understanding of the 
diseases molecular basis lead by the next-generation sequencing (Cheung et al., 2012; Reddy 
et al., 2010) associated with techniques such as phage display (Li and Caberoy, 2010; Saggy 
et al., 2012). 
 A patent scenario for the therapeutic mAb confirms the growth of the sector. 
Considering a patent search using the priority year consisting from 1998 to 2017 and the IPC 
class and subclasses of A61K 39/395 (Medicinal preparations containing antibodies), we 
found 75,796 patent families, with more than 5,000 inventions/year since 2004 (Fig. 1A). On 
the other hand, this large number of new inventions is inconsistent with the number of 
monoclonal antibodies in development. There are only 3,889 new drugs under development or 
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already registered or launched, and 70% of them are in the biological testing phase, the early 
stage of development (Fig.1 B). Nevertheless, the therapeutic class is facing the fastest 
approval rate in history, with the record of 10 approvals in 2017, totaling 76 mAbs approved 
either in US or EU (European Union) at the end of 2017 (The Antibody Society, 2017). And 
the quantity is about to rise because, at the same period, 9 therapeutics antibodies were 
undergoing regulatory review, 26 investigational are undergoing evaluation in late-stage 
clinical studies of non-cancer indications and more 28 for treatment of patients with cancer 
(Kaplon and Reichert, 2018).  
 
 
Figure 1: A) Evolution of therapeutic mAbs patent families according to earliest priority year of 
application (data retrieved from Derwent Innovation). B) Number of therapeutic mAbs under active 
development including those registered or launched (data retrieved from Clarivate Integrity) 
 
The US contribution to the drug discovery process related to therapeutic mAbs is very 
expressive. Most of the inventions from 1998 to 2017 comes from the US (56.5%), far ahead 
from the subsequent countries, which are Japan (14,28%) and European applications (7,96%) 
(Fig. 2A). Within the pool of technologies, the Roche group is the main player with 7,5% of 
the total, led by Hoffman La Roche and Genentech (an American biotech company acquired 
by Roche). From the top 20 assignees, 14 are US companies or American units (Fig. 2B). 
Despite the recent advances on the identification of new targets, the steps from the discovery 
and development to the commercial production of a new therapeutic mAbs are lengthy and 
costly (average of 1 billion from preclinical through to market approval), besides being 
scientifically and technically complex (Elgundi et al., 2017). Even so, it’s very worthful for a 
biotech company to invest this therapeutic mAbs, as they are the major class of 
biopharmaceutical products worldwide and often the first product candidates advancing to 
clinical trials (Ecker et al., 2015). 
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Figure 2: A) World map of the patent families’ distribution according to the priority country. The graph line 
represents the percentage of the patent counts of each country or office relative to the total. B) Bubble chart 
representing the top 20 assignees and its evolution from 2007 to 2015 (the last two years were not shown since 
the number of patents is decreased because of the publication window of 18 months) 
 
  2.2. Factors contributing to the therapeutic mAbs success 
As mentioned previously, the intellectual property acts as a central pillar for the 
therapeutic mAbs market, along with the strength of the company to lead their discoveries 
from bench to market. Supporting this pillar, are the clinical implications and therapeutic 
properties of the drug itself.  
In this manner, the success factors of a therapeutic mAbs comprehend three aspects. 
The attributes related to an efficient patent protection are very important to assure a sufficient 
return of investment on an environment of rapid technology change (Storz, 2011). Moreover, 
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biosimilar has come to the market reducing the drug’s cost and taking advantage of expired 
patents. Another relevant aspect is the attributes related to the company’s strategies to develop 
the mAbs since failure on steps from the discovery to the market approval significantly 
impairs the drug’s success. Among these multiple investments and strategies, an efficient 
R&D expenditure and collaboration among companies mark the sector of biopharmaceuticals 
(Moorkens et al., 2017; Schuhmacher et al., 2016). Finally, the success of a therapeutic mAbs 
is also dependent on the aspects related to its medical relevance related to the clinical 
attributes of the therapy.  
Thus, understanding which factors and key attributes related to them are more 
important for a novel mAbs being successful, will significantly assist the decision-making of 
a managerial sector of the biotech company. It has been reported that early decision-making 
reduces substantially the R&D costs by anticipating the trend of failure of a drug candidate 
(DiMasi et al., 2014). Decision-making methods such as HDM or Analytic Hierarchy Process 
(AHP) can serve as a proper alternative to analyze and quantify the factors that drive a 
therapeutic mAbs to success.   
 
2.3. Multi-criteria decision-making and its applications 
The HDM was created at the beginning of the 1980’s by Kocaoglu (1983). It is a 
multi-criteria decision-making (MCDM) methodology very similar to Saaty’s AHP (1980) 
with applications in multiple fields. HDM uses ration scale instead of eigen vectors in the case 
of AHP. In the case of HDM, the ratio scale used for judgment quantification method is the 
constant-sum method, which required experts to allocate 100 points between two decision 
variables at a time with respect to their relative importance to a higher level decision variable 
that they were associated with. Several recent studies demonstrated that use of constant sum 
method was more efficient in judgement quantification (Chan and Daim, 2018; Son and 
Sheikh, 2018) 
 The bulk of the method consists in depicting a problem or situation in a hierarchical 
manner. The model components, depth, and width will vary depending on each case, but 
usually, the first level represents the mission (i.e., the objective one is trying to achieve by 
building and applying the model) and the very last level represents the alternatives being 
considered to solve the problem and accomplish the mission. The levels in between first and 
last depict the attributes (criteria) related to the alternatives and that is important to the 
mission. 
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The application of the model consists of gathering a pool of subject matter experts who 
will validate and quantify the model. Validation occurs when experts analyze and vet the 
components used in the model, attesting that those are relevant and enough to represent the 
issue in question. Quantification occurs when experts compare the model components against 
each other regarding their importance. The comparison, as it happens in AHP, is done in a 
pair-wise fashion and yields the importance of each model component with regards to the 
overall mission. After defining the importance of each component, the alternatives (last level) 
are evaluated concerning each component, and calculations are done in order to reach the 
conclusion of which of the alternatives is the best choice for the referred mission, considering 
the proposed criteria and their importance. 
HDM and AHP are very well established decision-making techniques, having been 
used by researchers for several decades. Examples of researches applying both AHP and HDP 
are abundant in the literature. AHP has been shown to be an effective method to select 
healthcare-related improvement projects (Testik et al., 2017) and also to prioritize and select 
projects to invest using a variant form, named fuzzy-AHP (Shaygan and Testik, 2017). HDM 
has also been applied extensively and successfully in several areas. Estep (2015) utilized the 
methodology to evaluate R&D project proposals, creating a technology transfer (TT) score 
that informs technology managers in the project selection phase. Daim et al. (2017) used 
HDM to assess robotics technologies in the power sector, coupling it with Technology 
Development Envelope (TDE) in order to have insights into the future of these technologies 
that are used to create strategic roadmaps. Researchers have also been experimenting with the 
methodology to tackle healthcare-related issues such as analyzing how electronic health 
records are adopted (Mudavadi et al., 2016) and to rank technology alternatives that have the 
potential to increase the diffusion of teleconsultation (Alanazi et al., 2015).  
A few studies have been shown to apply MCDM in the biotechnology sector. Zahir 
(2002) used the AHP formulated in a Euclidian vector space to classify complex systems and 
objects in terms of its important attributes applied to the framework of plant genetics projects. 
Another study has made use of an AHP model to aid in the process of technology selection for 
a new product, in the context of a Chinese biotechnology firm (Zhang and Zhang, 2014). 
Wang et al (2013) have used the method to identify success factors in the adoption of ERP 
(Enterprise Resources Planning) systems for biotech companies and Chen and Wang (2010)  
analyzed biotech clusters using fuzzy AHP to produce academic and policy-making insights 
for the biotech sector. In a more straightforward application of the methodology, an AHP-
based model for biotechnology firms were developed to select green suppliers for their 
9 
 
operations (Nie, 2013). Although the decision methods have many applications, studies that 
combine these methods with technology assessment through patent scoring is still largely 
unexplored. The benefit of combining them would be leveraging expert judgement and 
technology intelligence data (patent scores) at the same time providing much better insight 
into technology assessment.  
 
2.4. Technology assessment and its association with decision-making models 
Technology assessment started out as an attempt, by the government, to evaluate 
technologies and the effect of those on people and on societal structures, most importantly the 
potential negative effects of it. Technology assessment studies would result in instructions and 
inputs for public institutions to design policies (Berg et al., 1976; Roessner and Frey, 1974; 
Van Den Ende et al., 1998; Watson, 1978; Wynne, 1975). Over time, and with the extinction 
of the Office of Technology Assessment – an Office created by the American Congress in the 
1970’s – the positioning and purposes of technology assessment started to change. Private 
sector entities started to use the approach as a way to improve business performance. Instead 
of conducting technology assessment only to understand the effects of technology on society, 
they were aiming to understand the effects new technologies would have on their businesses, 
once developed and applied. In other words, organizations would conduct technology 
assessment studies to choose and control technologies (Azzone and Manzini, 2008), bringing 
benefits towards their businesses (Ahmad and Christakis, 1979). 
 The use of multi-criteria and multi-perspective approaches has been a constant in 
technology assessment. Since the inception of the TOP (Technical; Organizational; Personal) 
analysis (Linstone, 1999), multiple research has been done over the years using similar 
approaches. Several studies have used a hierarchical model to conduct health technology 
assessment with different purposes, such as to aid the design of a patient care database for low 
back pain (Hogaboam et al., 2014); to assess solar photovoltaic technologies under the STEEP 
analysis (Social; Technical; Economic; Environmental; Political) (Sheikh et al., 2011). 
Similarly, Sloane et al. (2003) built an Analytic Hierarchy Process model to assess different 
characteristics and choose from different options of neonatal ventilators for hospitals. 
Patent data has also been used throughout the literature to aid technology assessment 
studies. Quintella et al. (2011) used both patents and scientific papers to map and assess the 
current state of development related to CO2 capture technologies. Dara and 
Sangamwar,(2014) used patent analysis to identify the most important new coming anti-
cancer-related patents from Indian institutions and assessed those in terms of treatment and 
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diagnosis, while also identifying areas for future research in the field. Trappey et al. (2014) 
looked at patent data and clinical reports to analyze the viability of new technology 
innovations in the field of dental implants. Daim et al (2006) combined patent analysis with 
other methods such as growth curves to forecast technologies including fuel cells, food safety 
and optical storage. Messeni Petruzzelli et al. (2015a) explored the influence of patents on 
other patents. Reitzig, (2004) developed a set of indicators for patent valuation for corporate 
purposes. 
Patents were also associated with MCDM to assess technology value. Using AHP, 
Chiu and Chen (2007) developed a scoring system for patents from a licensor view 
highlighting important criteria (qualitative and quantitative) and their weights. They use four 
main dimensions for patent valuation: technology essence, cost dimension, product market, 
and technology market. Although the research proposed by these authors is the most closely 
related to what we have proposed in the present research, it does not consider specific factors 
related to the technology itself and aspects related to particularities of the companies, as in 
biotech.  Therefore, our study establishes a MCDM consisting of 18 attributes sub-divided in 
three main factors concerning to the patent status, the profile of the company (ies) which 
holds the technology, and the medical relevance of the therapeutic mAbs, to determine an 
overall ES to a patent to predict its technology potential. 
 
3. RESEARCH FRAMEWORK 
3.1. Selection of the factors and attributes to build the model 
The factors and attributes that contribute to the success of a therapeutic mAbs were 
selected based on information retrieved from the literature in scientific articles dealing with 
subjects such as intellectual property rights, the mAbs market and the clinical features of 
mAbs therapies. The factors, its identified attributes, and definitions were used as input to 
build the model into the HDM software for further analysis by the experts. The validated 
version of the hierarchical model and the references which support the attribute’s choice is 
presented in the result section.   
3.2.Selection and description of the expert’s panel 
To search for experts, we performed a keyword search on research foundations website 
to identify grants related to mAbs development. We also invited prominent researchers in the 
field identified by sources of scientific, technical, and medical research information such as 
ScienceDirect, PubMed, and Google Scholar. Some experts were invited via recommendation 
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of medical principal investigators and researchers inside universities. The process of 
recruiting the subject matter experts was through snowball sampling or chain of referral.  
A total of 20 experts agreed to participate. The panel was diverse since the subject of 
the factors have few knowledge overlaps. Some experts have both knowledge regarding two 
or more factors, and those were selected to analyze more than one factor according to their 
expertise. The experts chosen to be part of the study include 9 academic researchers, 6 of 
them in the field of  innovation management and 3 in management of technology; 1 economist 
expert in patent valuation, 1 technology transfer office (TTO) agent, 1 university TTO vice-
coordinator; 1 CEO of a patent consultant firm; 2 IP consultant in a biotech company which 
develops mAbs; 1 a senior scientist and project manager at a biopharmaceutical company; 2 
postdoctoral researchers in mAbs development; and 2 university PI in mAbs development. 
From this list, a total of 10 experts answered the questions related to the topic of patent status, 
12 to the topic regarding the organization profile and 4 to the topic of medical relevance of 
mAbs. The model was submitted to the experts to perform the validation and subsequent pair-
wise comparison. Firstly, they quantified the importance of the three factors considering their 
relative importance in influencing the success of the mAb. Secondly, they quantified the 
model’s attributes under each factor using the same approach described previously. Lastly, 
they judged the desirability functions. 
3.3.Model’s validation and quantification 
Once the expert’s panel has been defined, the model was then shown to them and their 
inputs were recorded. The first step of the model application, as aforementioned, is the 
validation. All experts consulted agreed (or not) that the components which compose the 
model are necessary and enough to describe the problem at hand and to influence the mission. 
Next, proceeding to the quantification, each expert compared every component in the second 
level against each other (in pairs) and every component of the third level against each other 
(again, in pairs), judging the importance of those components regarding the level above them. 
At the end of the process, the results of the expert's pairwise comparisons yielded the 
importance of each model component (in terms of percentage), regarding its parent level 
(local importance) and regarding the mission (global importance).  
3.4.Desirability Functions 
To determine the “score” of each patent and the final ranking of patents, desirability 
functions were used. Described and utilized jointly with HDM in several past studies (Estep, 
2017; Gibson, 2016; Phan, 2013), desirability functions are a useful way of determining how 
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desirable a certain characteristic or feature is. For each of the model components, levels 
describing different possibilities for each component were created and experts were asked to 
assign values from 0 (least desirable) to 100 (most desirable) to the levels. Those desirability 
values are then plotted to generate a desirability curve for each of the model’s components. In 
turn, the desirability curves are contrasted with the characteristics of the patents, thus arriving 
at the value of each patent for each of the model components. If the patent had more than one 
assignee, the mean between the patent attribute’s desirability level was used for the score. 
Then the values are multiplied by the model components’ global importance and all partial 
score are summed up, hence the total score of that particular patent is obtained. The patents 
are then organized in a decreasing order regarding their scores, and the final patent ranking is 
generated.  
3.5.Selection of Patents 
The mAbs patents serve as alternatives in the model. To select the patents, we used the 
Integrity database from Clarivate Analytics which aggregates data from dugs which have an 
intention for further investment in clinical trials (usually indicated in the company’s annual 
report) or have initiated the development of the drug candidate (any phase). In the database, 
we used a search query for mAbs drugs using the product type field option of “drugs and 
biologics” section, then we retrieved the patent list relative to each drug identified. 
Subsequently, the patent list was filtered based on two main features. First, we defined the 
period concerning the patent priority year ranging the last five full years since the completion 
of the research (2013-2017). Second, we filtered the assignee country to US assignees-only or 
inventions originated from an institution unit based in the US. The detailed information from 
the patent list containing all the indicators using in this study were obtained from the Derwent 
Innovation database (Clarivate Analytics) by searching to the patent numbers and exporting 
the results on excel datasheet.   
3.6. Attribute’s information retrieval from selected patents 
To retrieve information concerning the three criteria, we use three main databases. For 
patent data, we use the Derwent Innovation from Clarivate Analytics (Philadelphia – USA). 
For information related to the company’s attributes, we take advantage of BCIQ module from 
BioCentury Publications Inc database (California – USA). For the medical, clinical relevance, 
and drug development report of the mAbs, we use information from the database Integrity 
also from Clarivate Analytics. Additionally, all molecules classified in the field on antibody 
mimetics including its essential information (targets, therapy, clinical phase stage and others) 
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were exported from Integrity to assess the attribute of “competing technologies”. 
Alternatively, we use information from CrunchBase (San Francisco) and Angellist (San 
Francisco) databases to get more detailed information from companies. 
4. RESULTS AND DISCUSSION 
4.1. Factors and attributes which influence the therapeutic mAb success 
Our model’s mission (1st level of the model) is to determine a score to select the most 
promising inventions related to therapeutic mAbs. To achieve it, we have identified three 
main factors which contribute to the therapeutic mAbs to be considered promising (2nd level 
of the model). Those are related to a proper patent protection and favorable status (“Patent 
Status”); the company’s profile to advance on the development of the mAbs from the 
discovery to market (“Company/Assignee profile”) and the medical relevance of the 
antibodies (“Medical Relevance”). Within each factor, we identified six attributes (3rd level of 
the model) driving the importance of each factor to achieve our mission. In the next section, 
we describe each one of them and their associated attributes.  
4.1.1. Patent Status Factor:  
 The market success of a therapeutic mAbs is strongly linked to an adequate patent 
protection, which involves a series of attributes. The first attribute we select is the patent 
independent claims. The subject-matter protected by the patent is legally conferred by the 
claims. The number of claims has extensively been used to assess the technology value of a 
patent (Jeong et al., 2016; Kim and Bae, 2017; Lee et al., 2007; Trappey et al., 2012). Each 
claim denoted an invention and consequently, the larger number of claims is directly 
correlated with the broader scope and usefulness of a patent. Another attribute included in the 
model is the patent citations, which have long been considered as a measure of impact and 
economic value of a technology (Carpenter et al., 1981; Narin et al., 1987). Patent citation 
links can also predicts emerging technologies (de Paulo and Porto, 2018; Pereira et al., 2018). 
We consider not only patent citation as well as Non-Patent Literature (NPL) citations since it 
is also an indicator of the value of a relevant technology (Callaert et al., 2006). The attributes 
related to the geographic coverage and expected life of a patent was considered, which 
represent the patent commercial scope and its term, respectively. The patent legal status was 
analyzed referring to the events during the lifetime of a patent such as patent abandonment, 
revocation for any reason and payments of maintenance fees. Assignees should proper protect 
and defend the patent maintenance to enjoy its benefits, if it is granted and active, it means 
that the owner expects some cash flows from the technology development (Serrano, 2010). 
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The last attribute was the patent technological scope, which was suggested by the experts 
during the validation phase. The scope is represented by the number of different technological 
fields covered by the technology. A wider scope is an indicator of both the breadth and 
originality of an invention as well as more valuable knowledge (Fernández-Ribas, 2010; 
Lanjouw and Schankerman, 2001). 
4.1.2. Company/Assignee Profile Factor:  
 For the attributes related to the companies that hold the patent, we identified six 
attributes as well. We consider the percentage of the revenue invested in R&D that represents 
the R&D intensity of a company to develop a therapeutic mAbs. The patent portfolio attribute 
is relevant for a company, not only as a result of an intense R&D activity but also for the 
value that can be extracted through the patent portfolio acting as knowledge stocks (Harlin 
and O’Connor, 2008). Another attribute is regarding the previously approved drugs by 
regulatory agencies, which denoted the company’s strength to fully develop the drugs that 
will reach the market and available human resources with both scientific and legal aspects of 
drug development. The regulatory affairs of a company exert many functions including 
interacting with regulatory authorities, preparing documents for regulatory submission, 
developing regulatory strategies, and interacting with company staff (Moyer, 2006), and 
previous experience with these responsibilities will facilitate the path to the drug's approval. It 
has been shown that start-ups lack some capabilities from a big-biotech which has 
accumulated experience over the years, and also from limited financial resources (Pisano, 
2006). Additionally, basic research developed in academia in some cases provides the initial 
intellectual property for a biotech company (Vallas et al., 2011). Due to these disparities 
among types of organization, we consider this attribute in our analysis. We also included two 
attributes related to cooperation, one dealing with technological cooperation measured by the 
patent co-ownership which impacts a patent value (Ma and Lee, 2008; Meyer, 2006) and 
another related to strategic alliances of the companies,  a key success factor for biotechnology 
companies (Ernst & Young, 2016; Moorkens et al., 2017). 
 4.1.3. Medical Relevance Factor:  
This factor englobes attributes related to antibody clinical relevance and its therapeutic 
properties. The attribute “major condition to be treated” was considered in the model since 
there are differences in usefulness and applications of the therapy, such as cancer being the 
most prominent and dominant area (Geng et al., 2015). The attributes concerning the drug 
development status and the clinical phase represent the development status not considering 
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the clinical stage, and the clinical phase itself, respectively. Both the development status, 
considering discontinuations, early phases, late phases and the clinical phase stage are 
important for a mAb success by overcoming the risks and difficulties which remains in this 
area. Some R&D programs show difficulties to reach later stages, such as anti-infective and 
neuropharmacological indications, considered high-risk investments (Geng et al., 2015). 
Conversely, immune-checkpoint inhibitors have been successful in clinical with positives 
responses in patients (Sharma and Allison, 2015). Thus, the antibody cellular mechanism was 
also considered in the model. The antibody’s type (chimeric, humanized, bispecific…) is also 
relevant due to the concerns of immunogenicity caused by fragments of mouse origins 
(Nelson et al., 2010). Some alternatives to antibodies, not belonging to the immunoglobulin 
family have been developed and it has already been tested in clinical trials threatening the 
stability of the mAbs market (Gebauer and Skerra, 2009; Storz et al., 2012). Thus, we add an 
attribute related to competing technologies, in order to consider the existence of alternatives 
to antibodies for the treatment of the same condition. Table 1 synthesizes the factors and 
attributes definition as well as the unit measure for each of them. 
Table 1 
Factor’s and attribute’s definitions and unit measure by each of them 
Factors and 
attributes 
Definition and unit measured Supported Refs. 
Patent’s Attributes  
Patent Independent 
Claims 
Number of patent independent claims  (Kim and Bae, 2017; Lee et 
al., 2007; Trappey et al., 2012) 
Citations Number of the forward citation and scientific 
references citations  
(Carpenter et al., 1981; Narin 
et al., 1987) 
Geographic coverage Patent geographic coverage measured by the 
number of INPADOC family members or by the 
triad application (US, EP, WO) 
(Guellec and Van 
Pottelsberghe De La Potterie, 
2000; Kim and Bae, 2017) 
Expected life  Years remaining for the “alive” patent (Kim and Bae, 2017) 
Legal Status Is there any opposition/litigation? Is there any lack 
of fee payment? Is the patent lapsed, annulled or 
denied for any reason? 
(Serrano, 2010) 
Patent Scope Number of 4-digit subclasses of the IPC the 
invention is allocated to 
(Fernández-Ribas, 2010; 
Lanjouw and Schankerman, 
2001) 
Assignee’s Attributes  
R&D Expenditure What is the revenue percentage invested in R&D by 
the patent holder? Is there any venture or angel 
capital? 
(Cozzens et al., 2005; DiMasi 
et al., 2016) 
Patent Portfolio Number of patents that the patent holder own (Harlin and O’Connor, 2008) 
Drugs approval by 
regulatory agencies 
Number of previously approved drugs by regulatory 
agencies. Are there any related to antibodies? 
(Moyer, 2006) 
Organization Type Is the patent holder a start-up, a university, big 
biotech, private company, government institution or 
the patent is in cooperation? 
(Pisano, 2006; Vallas et al., 
2011) 
Technological 
Collaboration 
The rate of technological cooperation measure by 
patent co-assignee frequency  
(Ma and Lee, 2008; Meyer, 
2006) 
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Strategic alliances Measure by the intensity rate of contractual 
agreements (franchising licensing and cross-
licensing), non-equity alliances (Joint R&D, joint 
product, long-term sourcing agreements) equity 
alliances, joint venture, and merge/acquisitions  
(Ernst & Young, 2016; 
Moorkens et al., 2017) 
Medical Relevance attributes  
Major condition group 
to be treated 
takes into consideration the relevance of the major 
condition group (clinical condition) to be treated by 
the therapeutic mAb, such as for cancer treatment, 
Anti-infective therapy, treatment of inflammation and 
hematological disorders, congenital malformations, or 
rare disease 
(Geng et al., 2015) 
Drug Development 
Status 
What is the stage of the drug development? 
Discontinued or withdrawal, biological testing in the 
laboratory only, pre-clinical or clinical, NDA, 
registered or marketed? 
(Geng et al., 2015; Kaplon and 
Reichert, 2018) 
Clinical Phase the stage of the clinical phase   (Tsai and Erickson, 2006) 
Antibody Cellular 
Mechanism 
Does the cellular mechanism of action relevant to 
the success of the antibody? The antibody acting as 
anti-inflammatory molecule, viral entry inhibitor, 
antimitotic and apoptosis inducer, angiogenesis 
inhibitor, immune checkpoint inhibitors or signal 
transduction modulators (targeting growth factors, 
receptors…) will influence its success in the near 
future? 
(Sharma and Allison, 2015; 
Topalian et al., 2015) 
Antibody Category Is the type of antibody relevant to the success of the 
molecule?  Is it a human mAb, or humanized, 
chimeric, bispecific, scFv, murine or recombinant 
mAb? 
(Nelson et al., 2010) 
Existence of 
Competing 
Technologies 
Factors related to the existence of any alternative to 
antibodies for the treatment of the same condition 
such as antibody mimetics targeting the same 
molecule? 
(Gebauer and Skerra, 2009; 
Storz, 2011) 
 
All factors and attributes along with its definitions were used to build the model to 
show to the expert panel for further validation and quantification. A previous version of the 
model was sent to the experts for validation and some minor modifications were suggested to 
reach the final version (Figure 3). Most experts suggested changes on the first version of the 
attribute “Patent Claims” to the “Patent Independent Claims”, and to insert a new attribute 
named “Patent Scope” to the “Patent Status” factor. In the “Company/Assignee Profile” 
factor, the experts suggested splitting the formerly technological collaboration into 
“Technological collaboration” and “Strategic alliances”. In the “Medical Relevance” factor, 
the experts suggested adding the attribute “Competing Technologies”.  
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Figure 3: The HDM model designed to determine an emerging technology score for therapeutic mAbs. Texts in 
red and orange boxes show modifications on the first version of the model suggested by the expert panel. 
 
4.2. The relative importance of the factors and attributes which influence the 
therapeutic mAbs success  
We took advantage of a HDM to quantify the relative importance of factors and 
attributes to build the ES parameters, considered as a ranking/rating patent valuation method 
(Razgaitis, 1999). After the submission of the model to the expert panels for the quantification 
of the first level, we performed the calculation of the importance score of each factor for the 
mission achievement. The experts should be able to answer which factor is most important for 
a mAb to become relevant in the future. The results reliability was obtained by controlling for 
inconsistency and disagreement. Leveraging metrics utilized in previous research (Estep, 
2017; Gibson, 2016; Phan, 2013), the inconsistency level was calculated for each expert, the 
disagreement level was calculated for each panel, and the acceptable threshold for both 
individual inconsistency and group disagreement was 0.1 (10%). Since, throughout the whole 
model application, inconsistency and disagreement levels were below the threshold, no 
corrective actions had to be taken. The properties of a therapeutic mAb have been long 
described as the most relevant to their usefulness (Clark, 1986) and the results showed that 
attributes related to the “Medical Relevance” contribute 50% for a mAbs to be considered 
promising. The attributes related to patent and the organization contributes 29% and 21% 
respectively (Figure 4).  
  
Patent Status Company/Assignee profile Medical Relevance 
Mean 0.29 0.21 0.5 
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Figure 4: Expert’s quantification relative to the model’s first level.  
 
The next step was submitting the model’s second level, the factors’ attributes, to 
experts perform the quantifications. At this step, the experts should be able to define a rate of 
importance to each attribute through pair-wise comparisons. Briefly, the results showed that 
in the “Patent Status” factor, the top three most important attributes are the patent scope and 
geographic coverage, both contributing 21%, followed by the patent citations, which 
contribute 16% to the factor. Similar to what we found, the commercial scope measured by 
the geographic coverage based on the number of patent members has been reported by 
another studies as an indicator of the economic value of a patent (Guellec and Van 
Pottelsberghe De La Potterie, 2000). Thus, protecting a mAb patent in multiple countries is a 
key attribute for a therapy to be considered emerging.   
As for the “Company/Assignee profile” factor, the attributes related to the pre-
existence of drugs approved by regulatory agencies contributes 23% to the factor’s 
importance, followed by the presence of strategic alliances and the R&D expenditure, with 
20% and 18% respectively. The investment in a biopharmaceutical approval is very costly and 
reflects the company’s robustness to lead a candidate to the market (Tsai and Erickson, 2006). 
Thus, previously approved drugs by regulatory agencies demonstrates not only the company's 
commitment to leading a candidate to the late stages of clinical studies, but also reinforces the 
importance of the company's expertise in meeting all requirements to approve a new drug 
usually led by the regulatory affairs. 
The most important attributes related to the “Medical Relevance” factor according to 
our model, is the drug’s clinical phase that contributes 21% of the factor importance, followed 
by the mAb mechanism of action (19%) and the clinical condition to be treated by the mAb 
(18%) (Figure 5). The mAb clinical phase stage represents a crucial step since lack of drug’s 
efficiency and safety tests as well as insufficient cash to lead the trials can absolutely restrict 
the biopharmaceutic to reach the market (Tsai and Erickson, 2006). 
  
Patent status 
Patent 
Independen
t Claims 
Citations 
Geographic 
coverage 
Expected 
life 
Legal Status Patent Scope 
Mean 0.12 0.16 0.21 0.15 0.16 0.21 
Minimum 0.08 0.01 0.13 0.08 0.06 0.07 
Maximum 0.2 0.38 0.35 0.2 0.26 0.47 
Std. Deviation 0.06 0.1 0.07 0.04 0.05 0.12 
Minimum 0.14 0.11 0.28 
Maximum 0.58 0.53 0.67 
SD 0.12 0.1 0.11 
Disagreement 0.096 
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Disagreement 0.071 
Organization 
profile 
R&D 
Expenditure 
Patent 
Portfolio 
Drugs 
approved 
Org. Type 
Tech.  
Collaboration 
Strategic 
alliances 
Mean 0.18 0.15 0.23 0.1 0.15 0.2 
Minimum 0.04 0.04 0.06 0.02 0.05 0.08 
Maximum 0.34 0.22 0.46 0.17 0.22 0.5 
Std. Deviation 0.09 0.05 0.14 0.05 0.06 0.11 
Disagreement 0.081 
Medical 
Relevance 
Major 
condition to 
be treated 
Drug Dev. 
Status 
Clinical 
Phase 
Antibody 
Cellular 
Mechanism 
Antibody 
Category 
Competing 
Techs. 
Mean 0.18 0.17 0.21 0.19 0.13 0.12 
Minimum 0.1 0.12 0.15 0.17 0.11 0.1 
Maximum 0.28 0.22 0.29 0.21 0.16 0.15 
Std. Deviation 0.07 0.04 0.06 0.02 0.02 0.02 
Disagreement 0.043 
Figure 5. The model’s 2nd level quantification results based on expert’s opinions of the six attributes of each 
factor considered in the study.  
 
Overall, among the 18 attributes analyzed in this study, the most important that 
contributes to a therapeutic mAb to be successful it’s the mAb clinical phase stage, 
accounting for 10% of the antibody’s ES (Figure 6). The results indicated that progress into 
later stages of clinical phase will likely lead to mAb success. Following the importance rate 
for the ES determination, the antibody mechanism of action is the second and the clinical 
condition to be treated by the mAbs the third most important attributes for the ES, 
contributing 9.5% and 9% to the model’s mission, respectively. For the whole model, the 
attribute with the least importance is the organization type, contributing only 2%. Despite the 
attributes relative to patents being fairly discussed as impacting a patent value, those 
associated to the biopharmaceutical company and the medical relevance of the antibodies 
through their relative importance identified in this study are unprecedent in the literature and 
depict what matters for a mAbs development to be successful. 
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Figure 6: The overall importance of the 18 attributes to achieve the model’s mission based on expert’s opinion. 
 
4.3. The desirability levels for the attributes 
The next step was the quantification of the desirability curves by the experts - 
allowing the judgment of whatever alternatives (patents) based on the desirability levels of 
each attribute. The higher the value of the desirability level the most desirable is the attribute 
to achieve its full importance (e.g. if drug clinical phase is relevant on a percentage of 10% to 
accomplish the mission, the experts will rank the desirability score of all levels such as pre-
clinical, phase I, phase II, Phase III or an already launched reaching the highest, lowest and 
intermediate desirability level). The experts quantified a total of 105 different levels 
distributed by the 18 attributes. The results were aimed to provide instructions to designate a 
score for each attribute according to the patent features, to finally consolidate the final ES for 
each patent. 
The desirability levels were based on the attribute meaning in which the least 
desirable, most desirable and levels in between were identified and quantified by the experts. 
For the patent factor, the most desirable level for a patent to be considered emerging is to 
contain more than 20 independent claims in the document (Fig. 7A), more than two citing 
patents (Fig. 7B), a broader geographic coverage with US, EP and WO applications (Fig. 7C), 
more than 15 valid years remaining (Fig. 7D),  a patent which was granted or under analysis 
(for any patent family member) (Fig. 7E), and with a wider scope consisting of 3 or more IPC 
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4-digit subclasses  (Fig. 7E). A perfect patent for our model will be the one which fulfills the 
highest desirability level. 
 
Figure 7: Desirability curves for the six attributes related to the “Patent Status” factor  
 
 For the desirability levels concerning the assignee profile, we noted some interesting 
findings. The most desirable level for the company to spend on R&D as a percentage of the 
revenue was between 15% to 20%, and, more than that is less desirable for a company to 
develop a successful mAbs biologic (Fig. 8A). Another interesting finding is the type of 
assignee. We observed that the most desirable level to achieve a promising patent is the co-
assignment of the patent as a result of cooperation among other assignees (such as 
Universities, research institutes or another company), which is more desirable than the patent 
holder being a big biotech company (Fig 8D).  The importance of cooperation was also 
highlighted through the desirable levels of technological cooperation and strategic alliances 
(Fig 8F). Joint venture and equity alliances such as merge and acquisitions are more desirable 
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than non-equity alliances, such as licensing, franchising, joint R&D, and some contractual 
agreements. The desirability level of the six attributes from the assignee profile factor is 
shown in figure 8 A-F. 
 
Figure 8: Desirability curves for the six attributes related to the “Assignee profile” factor. 1 Universities were 
included in the group. 2 The level was dependent on a patent being analyzed. 
 
 The medical relevance is the factor which aggregates the highest number of levels, 39 
levels at total, and some interesting conclusions must be highlighted. The therapeutic mAbs 
developed to treat cancer are the ones which received the most desirable level among the 
major condition group attribute (Fig. 9A). Drugs at the biological testing stage got only 25% 
of the attribute’s importance relative to the drug’s stage attribute (Fig. 9B). Antibodies 
inhibiting the immune checkpoint proteins are the most desirable concerning the mechanism 
of action (Fig. 9D). Chimeric antibodies are not only less desirable than murine monoclonal 
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antibodies, and human and humanized monoclonal antibodies are the most desirable (Fig. 9E). 
The desirability levels for the medical relevance attributes is shown in figure 9 A-F. 
 
Figure 9: Desirability curves for the six attributes related to the “Medical Relevance” factor 
4.4. Inferring the emerging score for a pool of therapeutic mAbs patents 
The next step of the research was to apply the model to a pool of patents related to 
therapeutic monoclonal antibodies, to identify those with the highest ES. As mentioned 
before, the US is the country with the largest biotech market and where more than a half of 
the inventions were originated. Thus, we selected lead compound and drugs under active 
development which has at least one US company as the patent holder by combining searches 
on Integrity and Derwent Innovation, both from Clarivate Analytics. Moreover, we define a 
temporal range consisting of recent inventions with the priority year between 2013 and 2017. 
In total, 1053 INPADOCs (International Patent Documentation), from 402 companies 
resulting in 709 drugs and biologics were selected as alternatives for further ranking. The 
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fundamental tool that allowed us to analyze such a large number of patents is the desirability 
functions. And, to the best of our knowledge, this is the first study that analyzed such a high 
number of alternatives (patents).  
To infer a score for each of the 18 attributes, we judge every unit measured from 
patents according to its desirability levels. The scores of the attributes score from patent 
status, assignee profile and medical relevance factors were integrated for each of the 1053 
patents. Figure 10 shows the distribution score of the three factors for each patent. The green 
dots represent patents adjusted by the patent status score (max 0.29), blue dots represent the 
assignee profile score and red dots the medical relevance score. For the patent assignee score, 
the minimum score identified was 0.1506 and the maximum 0.2820 (average 0.2073); for the 
assignee profile score, the minimum was 0.0309 and maximum 0.2029 (average 0.1386) and 
for the medical relevance score, the minimum was 0.2499 and the maximum 0.4855 (average 
0.3939). 
 
Figure 10: Distribution of the patent score for each of the three factors analyzed.  
 
 The total score for each patent was then calculated by the sum of the three factors 
score. A “perfect” patent in our model should be able to fill the highest desirability levels in 
all 18 attributes, reaching a score of 1. In our analysis, the maximum score found was 0.9436, 
which means that it misses only 5.6% of all factors combined. The minimum score was 
0.4711, which means that this patent has the less potential to be considered emerging 
according to factors and attributes analyzed by the study. The average of the total ES was 
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0.7398, a reasonable score for a technology emergence. The distribution of the total score is 
shown in figure 11.  
 
Figure 11: Distribution of total score for the 1053 patents analyzed (dots). Green dots represent the top 10 
patents with highest ES. 
 
 Patents included the top 10 according to the ES, highlighted in green at figure 11, 
bring some interesting information concerning the therapeutic mAbs (Table 2). From the list 
of 10 highest scored patents, nine have indications to treat cancer and one to treat asthma 
(US20150044204A1). Furthermore, nine of the ten deals with combination therapies instead 
of monotherapy of a therapeutic mAbs and eight has the PD-1 protein or its ligand PD-L1 as a 
target of the mAb.  Based on the features of the ten patents with the highest ES, we can 
generalize that the emerging technology for therapeutic mAbs is combination therapies of 
mAbs usually against PD-1 or PD-L1 aiming to boost the immune system to kill cancer cells.  
The biopharmaceutical Bristol Myers Squib owns three of the 10 patents with highest ES. 
Other players among the group are Merck & Company, Novartis (US unit) and Pfizer with 
two patents (as co-assignee or not) each.  
Table 2 
The list of the top 10 patents with highest ES 
ES Pub. Number mAb therapy description Assignee(s) 
0.9436 WO2015119923A1 
(2014) 
Combination of Anti-PD-1 + Agonist of 4-1BB (a 
co-stimulatory immune checkpoint molecule) 
Merck & Company 
| Pfizer INC 
0.9399 WO2016100882A1 
(2014) 
Combination of Anti-PD-1 (PD-L1, CTLA4, LAG3) 
+ Second Therapeutic Agent 
Novartis 
0.9336 WO2015026634A1 
(2013) 
Combination of Anti-PD-1 + dinaciclib (CDK 
inhibitor) 
Merck & Company 
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0.9277 WO2015179236A1 
(2014) 
Combination of Anti-CCR4 + Agonist of 4-1BB (a 
co-stimulatory immune checkpoint molecule) 
Kyowa Hakko 
Kirin | Pfizer INC 
0.9267 US20150044204A1 
(2013) 
Effective amount of Anti-CD125 Astrazeneca | 
Medimmune INC 
0.9263 WO2015042246A1 
(2013) 
Combination of Anti-PD-1 + Anti-LAG-3 Bristol-Myers 
Squibb 
0.9261 WO2016040892A1 
(2014) 
Combination of Anti-PD-1 (or PD-L1) + c-MET or 
CDK4/6 or PI3K or BRAF or FGFR or MEK or 
BCR-ABL inhibitor 
Novartis 
0.9256 WO2015134605A1 
(2014) 
Combination of Anti-PD-L1 + Anti-angiogenic 
tyrosine kinase inhibitor or an anti-CTLA-4 
Bristol-Myers 
Squibb 
0.9256 WO2015176033A1 
(2014) 
Combination of Anti-PD-L1 + another therapy used 
to treat lung cancer 
Bristol-Myers 
Squibb 
0.9230 WO2016081384A1 
(2014) 
Combination of Anti-PD-1 + Agonist of OX40 Roche | Genentech 
 
 
According to the overall patent score and the group of patents analyzed, there is not a 
perfect patent - the highest score found was 0.9436 out of 1. The patent with the highest score 
is a cooperation among Pfizer and Merck who deals with a combination therapy among the 
Pfizer’s 4-1BB agonist (PF-05082566) with the Merck’s PD-1 mAb named Keytruda 
(pembrolizumab) approved by FDA in 2014. In general, the majority of the patents included in 
the group of the top 10 highest scored deal with combination therapy using immune check-
point inhibitors (PD-1, PD-L1, CTLA4…). The successful application of the immune 
checkpoint blockers to treat cancer has recently triggered the development of a new generation 
of immune modulators which can be more effective if employed in combination (Topalian et 
al., 2015). Our results are supported by many studies published recently confirming this trend, 
reinforcing the strength of the model. Zarrabi and Wu (2018) reported that combination 
immunotherapies and combination immunotherapy with targeted therapy is shown as the most 
promising technologies and will have a profound effect at diminishing tumor resistance to 
therapy, median progression-free survival and overall survival in coming years. Massari et al., 
(2018) also mentioned that combination between immune-checkpoint inhibitors and other drugs 
such as target agents, chemotherapy, radiotherapy, other immune agents, and other immune-
checkpoint inhibitors could be a key strategy able to overcome the tumor immune escape. 
We found a very similar research which associates AHP to rank patents based on 
multiple experts evaluation for patent portfolio selection (Collan et al., 2013). The authors were 
the first to include both financial and non-financial metrics in ranking patents according to the 
moments, using probabilistic moments in characterizing fuzzy financial information. Although 
our study had similar aims, Collan and co-authors used six “strategic” criteria regarding the 
aspects of patents to build the decision model, while in our research the patent criteria were 
27 
 
based on quantitative and qualitative indicators of patents. The use of indicators have also been 
explored before in association with AHP for patent valuation (Chiu and Chen, 2007). In this 
study, the authors developed a patent scoring system from the licensor side which included 
dimensions both from patents and the market indicators. The patents indicators are very similar 
to the ones we selected for analysis, the difference consists in broader factors of the specific 
sector analyzed by our research, such as company’s attributes and intrinsic attributes of the 
technologies to be scored. 
 
5. CONCLUSIONS 
In the present research, we develop a model to predict the emergence of a therapeutic 
mAb based on several attributes relative to three main success factors: patent status, the 
company’s profile, and the medical relevance of the mAbs. The attributes quantification results 
along with its desirability levels provide enough information to rank any patent related to the 
field through the ES defined by the attributes importance. The most promising mAb deals with 
the combination therapies using immune checkpoint inhibitors associated with chemotherapy 
or immunotherapies. The model discussed hereby allows the forecasting of therapeutic mAbs 
on a patent-level with the highest probability of being emergent in the future according to the 
criteria analyzed.  
Our research has several managerial implications. Companies, research institutions and 
academia can take advantage of our model to manage their own portfolio as well as to study the 
portfolio from the competitors. The use of patent ranks can stimulate the decision-making to 
achieve the highest desirability levels described by our results to reinforce a technology to gain 
an emerging status in the near future. Our research is also useful to assess the value of patents 
for a near intention of licensing or technology transfer. Another implication is related to 
technology assessment as a way to improve business performance in order to choose and control 
technologies (Azzone and Manzini, 2008), bringing benefits towards their businesses (Ahmad 
and Christakis, 1979). The method applied in this study can be useful to measure the quality of 
a company’s whole patent portfolio as an increment in a decision to establish a strategic alliance 
such as mergers and acquisitions, a very frequent strategy in biotech. The present model was 
carefully distinguished and investigated in this paper. Thus, assured that the findings are not 
part of an exceptional model but adequate and tested model which stay relevant over the 
disciplines. Therefore, an emphasis indicates that company can generate value from the 
interchange and application of the model when examine patents which reflects on its 
competitive advantage. 
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In future studies, we intend to apply the present model to analyze other technological 
applications, both in the US and in other countries, considering also attributes related to market.  
A limitation of the study is the field of application, only biotech companies focused in 
developing monoclonal antibodies for a therapeutic use can take advantage of the model 
described herein. Another limitation is gathering data to apply the model to other sectors. The 
proper application of the model must be very consistent with the information management and 
availability of data from companies, patents and drugs (especially clinical trials). So, the 
application of the model in other countries will depend on the availability of such information 
to infer the score of technologies. 
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